合并乙型肝炎表面抗原阳性对结直肠癌肝转移风险的影响:4033例连续新诊断结直肠癌的回顾性临床研究
该回顾性研究纳入4033例连续新诊断且接受乙肝检测的结直肠癌患者,比较HBsAg阳性与阴性者同时性结直肠癌肝转移(synCRLM)的患病率。结果显示HBsAg阳性者synCRLM患病率显著更高(15.57% vs 8.60%,P < .001),HBsAg阳性是synCRLM最高的风险比(2.317,95%CI 1.406-3.820)。在HBsAg阳性患者中,无synCRLM者的FIB-4和APRI显著高于有synCRLM者。
要点
- HBsAg阳性结直肠癌患者同时性肝转移患病率为15.57%,高于HBsAg阴性者的8.60%(P < .001)。
- HBsAg阳性对同时性结直肠癌肝转移的风险比为2.317(95%CI 1.406-3.820)。
- HBsAg阳性且无肝转移者的FIB-4和APRI显著高于HBsAg阳性且有肝转移者。
核心结论
- 合并慢性HBV感染显著增加结直肠癌肝转移风险;对于HBsAg阳性结直肠癌患者,FIB-4/APRI升高可能具有抗转移作用;需进一步研究确定活跃HBV复制是否促转移。
研究设计与样本
- 回顾性临床研究,纳入4033例连续新诊断且接受乙肝检测的结直肠癌患者。
主要发现
- HBsAg阳性患者synCRLM患病率为15.57%,HBsAg阴性患者为8.60%,差异有统计学意义(P < .001,χ2检验)。
- Logistic回归分析显示HBsAg阳性对synCRLM的风险比为2.317(95%CI 1.406-3.820),为最高的风险比。
- HBsAg阳性且无synCRLM者FIB-4为1.23(0.92-1.88),HBsAg阳性且有synCRLM者为1.09(0.74-1.51),差异有统计学意义(P = .045,Mann-Whitney检验;均以中位数[第25-75百分位]表示)。
- HBsAg阳性且无synCRLM者APRI为0.23(0.227-0.387),HBsAg阳性且有synCRLM者为0.18(0.171-0.309),差异有统计学意义(P = .023,Mann-Whitney检验;均以中位数[第25-75百分位]表示)。
- HBsAg阳性且有synCRLM者HBeAg阳性率为26.32%,HBsAg阳性且无synCRLM者为18.45%,差异无统计学意义。
局限性
- 需进一步研究以确定活跃HBV复制是否促转移。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to evaluate the effect of chronic hepatitis B infection on the risk of synchronous colorectal liver metastasis (synCRLM). METHODS: A total of 4033 consecutive patients with newly diagnosed colorectal cancer (CRC) with hepatitis B testing were enrolled. The prevalence of synCRLM was compared between hepatitis B surface antigen (HBsAg)-positive and -negative patients; significant predictors for synCRLM were analyzed by logistic regression analysis; Fibrosis-4 Index for Liver Fibrosis (FIB-4), aspartate aminotransferase-to-platelet ratio index (APRI), and hepatitis B e antigen (HBeAg) status were compared between patients with or without synCRLM. RESULTS: The prevalence of synCRLM was significantly higher in the HBsAg+ patients than that in the HBsAg- patients (15.57% vs 8.60%; P < .001, χ2 test). A logistic regression analysis indicated that HBsAg+ showed the highest hazard ratio (2.317 [95% confidence interval, 1.406-3.820]) for synCRLM. Both FIB-4 and APRI were significantly higher in those with HBsAg positivity but no synCRLM compared to those with HBsAg positivity and synCRLM (FIB-4: 1.23 [0.92-1.88] vs 1.09 [0.74-1.51], P = .045; APRI: 0.23 [0.227-0.387] vs 0.18 [0.171-0.309], P = .023, Mann-Whitney test; all shown as median [25th-75th percentile]); HBeAg positivity was detected in 26.32% of those with positive HBsAg and synCRLM compared to 18.45% of those with positive HBsAg but no synCRLM; the difference was not statistically significant. CONCLUSIONS: Concomitant chronic HBV infection significantly increases the risk of CRLM, and for HBsAg+ CRC patients, elevated FIB-4/APRI may be antimetastatic. Further study is needed to determine whether active HBV replication is prometastatic.
引用
- Huo T, Cao J, Tian Y, et al. Effect of Concomitant Positive Hepatitis B Surface Antigen on the Risk of Liver Metastasis: A Retrospective Clinical Study of 4033 Consecutive Cases of Newly Diagnosed Colorectal Cancer. Clin Infect Dis. 2018. PMID: 29293940. doi:10.1093/cid/cix1118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。